One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1182/blood-2018-99-118966
Copy DOI Journal: Blood |  Publication Date: Nov 29, 2018 |
 Citations: 8 |
Affiliation: Ark Therapeutic (United States), City of Hope, City Of Hope National Medical Center, The University of Texas MD Anderson Cancer Center, Emory University, Boston Medical Center, Boston University, Duke University Hospital, Duke Medical Center, Moffitt Cancer Center, Dana-Farber Cancer Institute, The Ohio State University, Roswell Park Cancer InstituteResults of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
